Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

被引:0
|
作者
N Kröger
W Krüger
G Wacker-Backhaus
S Hegewisch-Becker
M Stockschläder
N Fuchs
B Rüssmann
H Renges
M Dürken
S Bielack
M de Wit
G Schuch
H Bartels
D Braumann
R Kuse
H Kabisch
R Erttmann
AR Zander
机构
[1] University-Hospital Hamburg-Eppendorf,Bone Marrow Transplantation Center and Department of Oncology/Hematology
[2] Hospital St Georg,Department of Hematology
[3] Hospital Altona,Department of Hematology/Oncology
[4] Community-Hospital,Department of Hematology
来源
关键词
bone marrow transplantation; total body irradiation; etoposide; Philadelphia chromosome-positive acute lymphoblastic leukemia;
D O I
暂无
中图分类号
学科分类号
摘要
We investigated an intensified conditioning regimen including fractionated total body irradiation (12 Gy), etoposide (30–45 mg/kg) and cyclophosphamide (120 mg/kg), followed by autologous (n = 5), allo-related (n = 13) or allo-unrelated (n = 6) bone marrow (n = 22) or peripheral stem cell (n = 2) transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. One patient received busulfan (16 mg/kg) instead of TBI. Nineteen patients were transplanted in 1CR, two in 2CR, one in 1PR and two in relapse. Major toxicity was mucositis grade II according to the Bearman scale in all patients. The treatment-related mortality was 25%, mainly due to infection or GVHD after allogeneic transplantation. After a median follow-up of 45 months (range 2–93), nine patients (37.5%) remain alive in CR. Nine patients (37.5%) relapsed and eight (33.3%) of these subsequently died. After autologous transplantation, four of five patients (80%) relapsed and died. Late relapse was seen after allogeneic, as well as autologous transplantation, at 33 and 59 months, respectively. The Kaplan–Meier estimate of leukemia-free survival for all patients is 38% at 3 years (95% CI: 18–58%) and 35% at 5 years (95% CI: 15–55%). For allogeneic transplants in first CR (n = 15) the estimate of disease-free survival was 46% at 3 years (95% CI: 19–73%) and 34% at 5 years (95% CI: 17–51%). Patients aged below 30 years had a better estimated overall survival at 3 years (61% vs 11%, P < 0.001). the bcr-abl fusion transcript (p210 vs p190 vs p210/190) did not affect disease-free or overall survival. In our experience, an intensified conditioning regimen seems to improve the results of bone marrow transplantation in patients with Ph+ acute lymphoblastic leukemia. However, the high relapse rate warrants novel approaches to enhance anti-leukemic efficacy.
引用
收藏
页码:1029 / 1033
页数:4
相关论文
共 50 条
  • [1] Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
    Kröger, N
    Krüger, W
    Wacker-Backhaus, G
    Hegewisch-Becker, S
    Stockschläder, M
    Fuchs, N
    Rüssmann, B
    Renges, H
    Dürken, M
    Bielack, S
    de Wit, M
    Schuch, G
    Bartels, H
    Braumann, D
    Kuse, R
    Kabisch, H
    Erttmann, R
    Zander, AR
    [J]. BONE MARROW TRANSPLANTATION, 1998, 22 (11) : 1029 - 1033
  • [2] Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
    Dunlop, LC
    Powles, R
    Singhal, S
    Treleaven, JG
    Swansbury, GJ
    Meller, S
    Pinkerton, CR
    Horton, C
    Mehta, J
    [J]. BONE MARROW TRANSPLANTATION, 1996, 17 (03) : 365 - 369
  • [3] BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
    FORMAN, SJ
    ODONNELL, MR
    NADEMANEE, AP
    SNYDER, DS
    BIERMAN, PJ
    SCHMIDT, GM
    FAHEY, JL
    STEIN, AS
    PARKER, PM
    BLUME, KG
    [J]. BLOOD, 1987, 70 (02) : 587 - 588
  • [4] Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia
    A Sharathkumar
    E F Saunders
    Y Dror
    R Grant
    M Greenberg
    S Weitzman
    H Chan
    S Calderwood
    M H Freedman
    J Doyle
    [J]. Bone Marrow Transplantation, 2004, 33 : 39 - 45
  • [5] Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Sharathkumar, A
    Saunders, EF
    Dror, Y
    Grant, R
    Greenberg, M
    Weitzman, S
    Chan, H
    Calderwood, S
    Freedman, MH
    Doyle, J
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 (01) : 39 - 45
  • [6] Philadelphia chromosome-positive Acute Lymphoblastic Leukemia
    Forghieri, Fabio
    Luppi, Mario
    Potenza, Leonardo
    [J]. HEMATOLOGY, 2015, 20 (10) : 618 - 619
  • [7] Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Ravandi, Farhad
    Kebriaei, Partow
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (05) : 1043 - +
  • [8] Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Foa, Robin
    Chiaretti, Sabina
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (25): : 2399 - 2411
  • [9] Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Hanane, W.
    Siham, C.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S312 - S312
  • [10] Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
    Shuichiro Takashima
    Toshihiro Miyamoto
    Tomohiko Kamimura
    Goichi Yoshimoto
    Shuro Yoshida
    Hideho Henzan
    Ken Takase
    Koji Kato
    Yoshikiyo Ito
    Yuju Ohno
    Koji Nagafuji
    Tetsuya Eto
    Takanori Teshima
    Koichi Akashi
    [J]. International Journal of Hematology, 2015, 102 : 689 - 696